NPPA revises ceiling prices of 93 scheduled formulations, Details

Published On 2023-01-12 12:30 GMT | Update On 2023-10-28 06:35 GMT

New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), the Ministry of Chemicals & Fertilizers, the Government of India, has revised the ceiling price of 93 scheduled formulation under the Drugs (Price Control) Order,2013.

The list of 93 scheduled formulations includes Sulfasalazine, Digoxin, Ethambutol, Phenytoin, Ceftriaxone, Cefotaxime, Ampicillin, Metoprolol, Fluconazole, Pyrazinamide, Phenobarbitone,

Amiodarone, Metronidazole, Acetazolamide, Clonazepam, and others.

Scheduled formulations are any formulation, included in the First Schedule whether referred to by generic versions or brand name (mainly products covered under National List of Essential Medicines are Scheduled Formulation). In other words, all medicines that are covered in National List of Essential Medicine, which are notified in Schedule 1, by the Govt. are scheduled formulation.

"Ceiling Price" refers to a price fixed by the Government for Scheduled Formulations in accordance with the provisions of drugs (prices control) order, 2013. Ceiling Price is the Maximum Price to Retailer (excluding Taxes, if any)for the given product.

This notice declared that in exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May 2013 and S.O. 5249(E) dated 11th November 2022 issued by the Government of India the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No SO 1499(E) dated 30th March 2022 in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession,the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Sl. No.	Name of the Scheduled Formulation	Dosage form and strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
1	Sulfasalazine	Tablet 500 mg	1 Tablet	4.21
2	Digoxin	Tablet 0.25mg	1 Tablet	1.19
3	Ethambutol	Tablet 600mg	1 Tablet	3.64
4	Phenytoin	Tablet 300mg	1 Tablet	4.89
5	Atazanavir (A) +Ritonavir(B)	Tablet 300mg(A) + Tablet 100mg(B)	1 Tablet	89.03
6	Ceftriaxone	Powder for Injection 500 mg	1 Vial	44.84
7	Ceftriaxone	Powder for Injection 250 mg	1 Vial	25.28
8	Ceftriaxone	Powder for Injection 1000mg	1 Vial	55.64
9	Ceftriaxone	Powder for Injection 2000mg	1 Vial	123.18
10	Cefotaxime	Powder for Injection 250 mg	1 Vial	15.80
11	Cefotaxime	Powder for Injection 500 mg	1 Vial	21.74
12	Cefotaxime	Powder for Injection 1000mg	1 Vial	35.64
13	Piperacillin (A) +Tazobactam(B)	Powder for Injection 1000mg(A)+125mg(B)	1 Vial	88.88

Sl. No.	Name of the Scheduled Formulation	Dosage form and strength	Unit	Ceiling Price (Rs.)
14	Piperacillin (A) +Tazobactam(B)	Powder for Injection 2000mg(A)+250mg(B)	1 Vial	170.83
15	Piperacillin (A) +Tazobactam(B)	Powder for Injection 4000mg(A)+500mg(B)	1 Vial	356.21
16	Ampicillin	Powder for Injection 500 mg	1 Vial	12.71
17	Metoprolol	Tablet 25mg	1 Tablet	3.75
18	Metoprolol	Tablet 50mg	1 Tablet	5.21
19	Propranolol	Tablet 40mg	1 Tablet	2.87
20	Fluconazole	Tablet 200mg	1 Tablet	15.57
21	Ethambutol	Tablet 800mg	1 Tablet	4.42
22	Pyrazinamide	Tablet 1000mg	1 Tablet	9.39
23	Pyrazinamide	Tablet 500mg	1 Tablet	4.36
24	Pyrazinamide	Tablet 750mg	1 Tablet	6.43
25	Phenobarbitone	Tablet 30mg	1 Tablet	1.17
26	Amiodarone	Tablet 200mg	1 Tablet	10.27
27	Ethambutol	Tablet 400mg	1 Tablet	2.33
28	Fluconazole	Tablet 100mg	1 Tablet	6.80
29	Azathioprine	Tablet 50mg	1 Tablet	10.04
30	Allopurinol	Tablet 100mg	1 Tablet	1.69
31	Propranolol	Tablet 10mg	1 Tablet	1.17
32	Hydroxychloroquine	Tablet 200mg	1 Tablet	5.67
33	Carbimazole	Tablet 10mg	1 Tablet	3.80
34	Cefixime	Tablet 200mg	1 Tablet	8.72
35	Imatinib	Tablet 100mg	1 Tablet	62.21
36	Tamoxifen	Tablet 20mg	1 Tablet	2.63
37	Tamoxifen	Tablet 10mg	1 Tablet	1.97
38	L-Asparaginase	Powder for Injection 5000 KU	1 Vial	922.94
39	L-Asparaginase	Powder for Injection 10000KU	1 Vial	1523.03
40	Dacarbazine	Powder for Injection 200mg	1 Vial	340.46
41	Mefloquine	Tablet 250 mg	1 Tablet	46.52
42	Thalidomide	Capsule 50 mg	1 Capsule	27.79
43	Thalidomide	Capsule 100mg	1 Capsule	55.31
44	Clonazepam	Tablet 0.25mg	1 Tablet	1.80
45	Clonazepam	Tablet 0.5mg	1 Tablet	3.08
46	Clonazepam	Tablet 1mg	1 Tablet	4.25
47	Clozapine	Tablet 25mg	1 Tablet	2.48
48	Clozapine	Tablet 50mg	1 Tablet	4.63
49	Clozapine	Tablet 100 mg	1 Tablet	7.54

Sl. No.	Name of the Scheduled Formulation	Dosage form and strength	Unit	Ceiling Price (Rs.)
50	Metronidazole	Tablet 200mg	1 Tablet	0.73
51	Metronidazole	Tablet 400mg	1 Tablet	1.36
52	Hydroxyurea	Capsule 500mg	1 Capsule	10.81
53	Ibuprofen	Tablet 200mg	1 Tablet	0.63
54	Acetazolamide	Tablet 250mg	1 Tablet	3.62
55	Ciprofloxacin	Tablet 250mg	1 tablet	1.96
56	Salbutamol	Tablet 4 mg	1 Tablet	0.19
57	Salbutamol	Tablet 2 mg	1 Tablet	0.16
58	Metoclopramide	Tablet 10mg	1 Tablet	1.20
59	Amoxicillin (A) +Clavulanic acid (B)	Tablet 500 mg (A) + 125 mg (B)	1 Tablet	16.32
60	Docetaxel	Powder for Injection 20mg	1 Vial	2558.14
61	Clopidogrel	Tablet 75mg	1 Tablet	5.94
62	Hydrocortisone	Powder for Injection 100mg	1 Vial	39.95
63	Gemcitabine	Powder for Injection 1000mg	1 Vial	4987.65
64	Methotrexate	Tablet 10mg	1 tablet	11.85
65	Methotrexate	Tablet 2.5mg	1 tablet	4.74
66	Diltiazem	Tablet 60mg	1 Tablet	4.87
67	Amiodarone	Tablet 100mg	1 Tablet	5.48
68	Dom1idone	Tablet 10mg	1 Tablet	2.06
69	Quinine	Tablet 300 mg	1 Tablet	5.04
70	Enalapril	Tablet 5mg	1 Tablet	3.30
71	Enalapril	Tablet 2.5mg	1 Tablet	1.95
72	Acyclovir	Tablet 400mg	1 Tablet	12.18
73	Acyclovir	Tablet 200mg	1 Tablet	6.79
74	Rifampicin	Capsule 450mg	1 Capsule	5.06
75	Zidovudine (A) +Lamivudine(B)	Tablet 300mg(A)+150mg(B)	1 Tablet	18.81
76	Primaquine	Tablet 7.5mg	1 Tablet	2.12
77	Nitrofurantoin	Tablet 100 mg	1 Tablet	7.23
78	Ciprofloxacin	Tablet 500mg	1 tablet	3.79
79	Ondansetron	Tablet 8 mg	1 Tablet	7.94
80	Griseofulvin	Tablet 250mg	1 Tablet	1.58
81	Escitalopram	Tablet 5mg	1 Tablet	4.48
82	Escitalopram	Tablet 10mg	1 Tablet	8.03
83	Escitalopram	Tablet 20mg	1 Tablet	12.81
84	Gemcitabine	Powder for Injection 200 mg	1 Vial	1159.21
85	Ceftazidime	Powder for Injection 1000mg	1 Vial	202.47
86	Diclofenac	Tablet 50mg	1 Tablet	1.83

Sl. No.	Name of the Scheduled Formulation	Dosage form and strength	Unit	Ceiling Price (Rs.)
87	Carbamazepine	Tablet 200mg	1 Tablet	1.40
88	Amoxicillin (A) + Clavulanic acid (B)	Powder for Injection 1 g (A) +200mg (B)	1 Vial	125.44
89	Bisacodyl	Tablet 5mg	1 Tablet	1.04
90	Pantoprazole	Injection 40mg	1 Vial	45.00
91	Ethinylestradiol (A)+ Levonorgestrel (B)	Tablet 0.03mg(A) + Tablet 0.15mg(B)	1 Tablet	2.83
92	Norethisterone	Tablet 5mg	1 Tablet	4.81
93	Carbimazole	Tablet 5mg	1 Tablet	1.95

The Notice further added:

(a) All manufacturers of scheduled formulation, selling the branded or generic or both versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.

(b) All the existing manufacturers of the above-mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above-said table.

(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of the Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner to be easily accessible to any person wishing to consult the same.

(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO 2013 such existing manufacturer shall apply for prior price approval of a such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(g) The manufacturers of above said scheduled formulations shall furnish a quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with the Essential Commodities Act,1955.

(i) Consequent to the issue of the ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above-said date of notification, stand(s) superseded.

Also Read:NPPA Extends Ceiling Price Of LMO,Oxygen Inhalation Till March 31,2023

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

NPPA revises ceiling prices of 93 scheduled formulations, Details

Similar News

Zydus Secures CDSCO Panel Go-Ahead For Phase III Trial of Empagliflozin-Metoprolol FDC

Reckitt names Karandeep Singh Duggal as new Region Head-Central India

Cipla inks pacts to invest in iCaltech Innovations

Dr Reddy's Labs gets USFDA EIR for New York facility

Sanofi to expand respiratory vaccines pipeline with acquisition of Vicebio

JnJ seeks USFDA approval for Icotrokinra to treat plaque psoriasis in adults, adolescents

Bayer Nubeqa gets EU nod in third indication for advanced prostate cancer

1-Year Ban for Fake Docs, Mandatory Disposal of Near-Expiry Stock: CDSCO Revises Pharma Export Rules